Acadia Pharmaceuticals

Acadia wins first FDA approval for Rett syndrome drug
Acadia wins first FDA approval for Rett syndrome drug
Endpoints
Acadia Pharmaceuticals
FDA
Daybue
Rett Syndrome
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
5 FDA decisions to watch in the first quarter
5 FDA decisions to watch in the first quarter
BioPharma Dive
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
Acadia hits another Nuplazid roadblock as the FDA doles out CRL and recommends another trial
Acadia hits another Nuplazid roadblock as the FDA doles out CRL and recommends another trial
Endpoints
Acadia Pharmaceuticals
Nuplazid
FDA
complete response letter
Alzheimer's disease psychosis
Flag link:
Acadia's Alzheimer’s Drug Voted Down by FDA Advisory Committee
Acadia's Alzheimer’s Drug Voted Down by FDA Advisory Committee
BioSpace
Acadia Pharmaceuticals
Nuplazid
FDA
Alzheimer's disease
Flag link:
A year after CRL, Acadia is going back to bat for Nuplazid at the FDA
A year after CRL, Acadia is going back to bat for Nuplazid at the FDA
Endpoints
Acadia Pharmaceuticals
FDA
Nuplazid
Alzheimer's disease psychosis
Flag link:
Late-stage pain pipeline refuses to swell
Late-stage pain pipeline refuses to swell
EP Vantage
painkillers
Vertanical
Teva Pharmaceutical
Regeneron
Ampio Pharmaceuticals
Biogen
Eli Lilly
Vertex Pharmaceuticals
AstraZeneca
Acadia Pharmaceuticals
Flag link:
Acadia's prized pain drug from $52M buyout flops its first test
Acadia's prized pain drug from $52M buyout flops its first test
Endpoints
Acadia Pharmaceuticals
CerSci Therapeutics
M&A
ACP-044
non-opioid pain treatments
Flag link:
FDA panel to review once-rejected Acadia drug for psychosis
FDA panel to review once-rejected Acadia drug for psychosis
BioPharma Dive
Acadia Pharmaceuticals
FDA
Nuplazid
Alzheimer's disease psychosis
Flag link:
Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer's dementia nod without extra studies
Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer's dementia nod without extra studies
Fierce Pharma
Acadia Pharmaceuticals
Nuplazid
dementia
Alzheimer's disease psychosis
Flag link:
Three Pharma Companies Seek to Address FDA Rejections
Three Pharma Companies Seek to Address FDA Rejections
BioSpace
FDA
Iterum
sulopenem
Eton Pharmaceuticals
Acadia Pharmaceuticals
Nuplazid
Flag link:
Big pharma leads the way in stock market resurgence
Big pharma leads the way in stock market resurgence
EP Vantage
Big Pharma
pharma stocks
Acadia Pharmaceuticals
AstraZeneca
Biogen
Eli Lilly
GSK
Merck
Moderna Therapeutics
Novartis
Sanofi
Provention Bio
Flag link:
FDA rejects Acadia’s bid for Nuplazid approval in dementia-related psychosis
FDA rejects Acadia’s bid for Nuplazid approval in dementia-related psychosis
MedCity News
Acadia Pharmaceuticals
Nuplazid
dementia-related psychosis
FDA
Flag link:
5 FDA approval decisions to watch in the second quarter
5 FDA approval decisions to watch in the second quarter
BioPharma Dive
FDA
Biogen
aducanumab
Acadia Pharmaceuticals
pimavanserin
AstraZeneca
vaccines
COVID-19
Sanofi
Avalglucosidase alfa
Pfizer
pneumococcal disease
Flag link:
Acadia's surprise Nuplazid snag—and subsequent cold shoulder at FDA—beg more questions than answers
Acadia's surprise Nuplazid snag—and subsequent cold shoulder at FDA—beg more questions than answers
Fierce Pharma
Acadia Pharmaceuticals
FDA
Nuplazid
Parkinson's Disease Psychosis
Flag link:
Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout
Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout
Xconomy
Acadia Pharmaceuticals
M&A
CerSci Therapeutics
post-surgical pain
nerve pain
Flag link:
2 Biotech Stocks Poised to Soar in 2020
2 Biotech Stocks Poised to Soar in 2020
Motley Fool
Acadia Pharmaceuticals
Axsome Therapeutics
M&A
Flag link:
Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis
Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis
Xconomy
Acadia Pharmaceuticals
cilnical trials
Parkinson's Disease Psychosis
dementia-related psychosis
Flag link:
Top 7 Companies in Biotech Beach by Revenue
Top 7 Companies in Biotech Beach by Revenue
BioSpace
Biotech Beach
San Diego
California
Amgen
Neurocrine
Acadia Pharmaceuticals
Retrophin
Tocagen
Mirati Therapeutics
AnaptysBio
Flag link:

Pages